Skip to main content
OMER
NASDAQ Life Sciences

Omeros Retires Another $14.5M in Convertible Notes, Bringing Total Buyback to $30.5M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$9.59
Mkt Cap
$696.975M
52W Low
$3.34
52W High
$17.65
52W Position info
187% above low
Off High info
46% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

OMER has more than doubled off its 52-week low of $3.34.

Summary

By retiring another $14.5 million of its 2029 convertible notes, Omeros further reduces potential dilution and highlights its financial strength after returning to profitability.


Key Events · Financing and Capital Events · OMER

  • Note Repurchase Completed

    A total of $14.5 million principal amount of 9.50% Convertible Senior Notes due 2029 was repurchased for $29.0 million, a sum that includes accrued interest and obligations.

  • Total Debt Reduction

    When combined with prior repurchases, the company has now retired $30.5 million of the notes, leaving $40.3 million outstanding.

  • Dilution Risk Mitigated

    Retiring convertible notes reduces potential future share dilution, a clear positive for existing shareholders.

  • Follows Prior Buyback Programs

    This repurchase is part of a series of note buybacks announced in June and July 2026, reflecting a strategy to clean up the balance sheet.


Analysis · OMER · Life Sciences

The company completed a repurchase of $14.5 million in convertible notes for $29 million, pushing total retired debt to $30.5 million. This move curtails future dilution risk from the 2029 notes and underscores management's confidence in cash generation following the YARTEMLEA launch. With $40.3 million in notes still outstanding, the remaining overhang appears manageable.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OMER was trading at $9.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $697M. The 52-week trading range was $3.34 to $17.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OMER - Latest Insights

OMER
Nov 16, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.00
Real-time Price: $15.40 info
Change: +$0.4042 (+3%) info
Market Cap: $1.207B info
OMER
Nov 16, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $17.53
Real-time Price: $15.40 info
Change: -$2.13 (-12%) info
Market Cap: $1.207B info
OMER
Oct 16, 2026, 6:19 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $17.05
Real-time Price: $15.40 info
Change: -$1.65 (-10%) info
Market Cap: $1.207B info
OMER
Aug 12, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.11
Real-time Price: $15.40 info
Change: -$0.710 (-4%) info
Market Cap: $1.207B info
OMER
Aug 12, 2026, 4:10 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $15.60
Real-time Price: $15.40 info
Change: -$0.200 (-1%) info
Market Cap: $1.207B info